RESUMO
Resumen. Objetivos. Evaluar los atributos psicométricos de la Scales for Outcomes in Parkinsons Disease-Psychosocial (SCOPA-PS) en España, y compararlos con los estudios previos. Pacientes y métodos. Estudio multicéntrico y transversal sobre 387 pacientes con enfermedad de Parkinson (EP), el 70% en estadios Hoehn y Yahr (HY) 2 o 3, con edad media 65,8 ± 11,1 años y 8,1 ± 6 años de evoluación. Se aplicaron las siguientes medidas: SCOPA-Motor, SCOPA-Cognición, Parkinsons Psychosis Rating Scale modificada, índice de impresión clínica de gravedad (CISI-PD), Cumulative Illness Rating Scale- Geriatrics, SCOPA-Autonómica, SCOPA-Sueño, escala hospitalaria de ansiedad y depresión (HADS), escalas visuales analógicas de dolor y fatiga, EQ-5D y SCOPA-PS. Se analizaron la aceptabilidad, consistencia interna, dimensionalidad, validez de constructo y precisión de la SCOPA-PS. Resultados. El índice sumarial de la SCOPA-PS no mostró efecto suelo o techo. La consistencia interna fue satisfactoria (alfa = 0,85; correlación ítem-total => 0,39). Se identificaron dos factores (un 53,5% de la varianza). La SCOPA-PS mostró una alta correlación (rS => 0,50) con el índice EQ-5D, HADS, SCOPA-Motor y SCOPAAutonómica, y moderada (rS = 0,35-0,49) con CISI-PD, fatiga y HY. La SCOPA-PS discriminó significativamente entre pacientes agrupados por estadios HY, niveles de gravedad del CISI-PD, grupos de edad y de duración de la EP. El error estándar de la medida resultó 7,24 ± 18,7. En conjunto, estos hallazgos concuerdan con estudios previos. Conclusión. La SCOPAPS es una escala con aceptabilidad satisfactoria, consistente, válida y precisa para evaluar el impacto psicosocial de la EP (AU)
Summary. Aims. To evaluate the psychometric attributes of the Scales for Outcomes in Parkinsons Disease-Psychosocial (SCOPA-PS) in Spain and to compare them with previous studies. Patients and methods. We performed a multi-centre, crosssectional study of 387 patients with Parkinsons disease (PD), 70% of whom were in Hoehn and Yahr (HY) stages 2 or 3, with a mean age of 65.8 ± 11.1 years and 8.1 ± 6 yearsprogression. The following measures were applied: SCOPA-Motor, SCOPACognition, modified Parkinsons Psychosis Rating Scale, Clinical Impression of Severity Index for Parkinsons Disease (CISIPD), Cumulative Illness Rating Scale-Geriatrics, SCOPA-Autonomic, SCOPA-Sleep, Hospital Anxiety and Depression Scale (HADS), Fatigue and Pain Visual Analogue Scales, EQ-5D and SCOPA-PS. Acceptability, internal consistence, dimensionality, construct validity and precision of the SCOPA-PS were analysed. Results. The SCOPA-PS summary index displayed no ceiling or floor effect. Internal consistence was satisfactory (alpha = 0.85; item-total correlation => 0.39). Two factors were identified (53.5% of the variance). The SCOPA-PS was highly correlated (rS => 0.5) with the HADS, SCOPA-Motor, SCOPA-Automatic and EQ-5D index, and moderately so (rS = 0.35-0.49) with CISI-PD, fatigue and HY. The SCOPA-PS discriminated significantly between patients grouped according to HY stages, levels of severity of the CISI-PD, age groups and length of time with PD. The standard error of the measure was 7.24 ± 18.7. As a whole, these findings are in agreement with previous studies. Conclusions. The SCOPA-PS is a scale with a satisfactory degree of acceptability, and it is consistent, valid and precise for evaluating the psychosocial impact of PD (AU)
